SEC Form 4 · accession 0001144204-15-037051
Edesa Biotech, Inc. · EDSA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel E. Morse
Director
Period of report
Jun 10, 2015
Accepted (ET)
Jun 15, 2015 · 6:03 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001540159
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F2 | $0.72 | Jun 10, 2015 | A | 25,000 | A | — | Jun 10, 2022 | Common Shares | 25,000 | 25,000 | D |
Explanation of responses
- F1The options are exercisable at a price of C$0.89. The U.S. dollar price reported on this Form 4 in column 2 reflects the U.S. dollar equivalent exercise price on the date of grant, calculated at the closing price for cable transfers in Canadian dollars as reported by Bloomberg on such date of U.S. $1.00=CDN$1.23
- F2One-third of the option vested immediately, one-third of the option vests on the first anniversary of June 10, 2015, and one-third vests 18 months after June 10, 2015.